Trials / Completed
CompletedNCT04051463
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Prospective Randomized Study to Determine Whether Use of Rhopressa™ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Price Vision Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Netarsudil Ophthalmic Solution | Netarsudil eye drops instilled once daily |
| DRUG | Placebo | Placebo eye drops instilled once daily |
Timeline
- Start date
- 2019-08-05
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2019-08-09
- Last updated
- 2021-10-19
- Results posted
- 2021-09-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04051463. Inclusion in this directory is not an endorsement.